Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
| ▸ | MARS1 | P56192 | 11/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.34 |
| ▸ | BHMT | Q93088 | 1/20 | 0.32 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.32 |
| ▸ | PPID | Q08752 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL1764302 | 0.92 | MARS1 (0.33) | METAP2METAP1RNPEPMARS1ANPEP | |
| Serine SCHEMBL5577056 | 0.89 | RNPEP (0.37) | METAP2METAP1RNPEPMARS1BHMT | |
| SCHEMBL542056 | 0.87 | RNPEP (0.37) | METAP2METAP1RNPEPMARS1ANPEP | |
| SCHEMBL16513337 | 0.87 | METAP2 (0.40) | METAP2METAP1RNPEPMARS1ANPEP | |
| Threonine SCHEMBL6367180 | 0.87 | METAP2 (0.35) | METAP2METAP1RNPEPMARS1BHMT | |
| SCHEMBL162031 | 0.87 | RNPEP (0.42) | METAP2METAP1RNPEPMARS1ANPEP | |
| SCHEMBL6045793 | 0.87 | RNPEP (0.42) | METAP2METAP1RNPEPMARS1ANPEP | |
| SCHEMBL20996747 | 0.87 | RNPEP (0.42) | METAP2METAP1RNPEPMARS1ANPEP | |
| SCHEMBL5617582 | 0.87 | RNPEP (0.42) | METAP2METAP1RNPEPMARS1ANPEP | |
| Leucine SCHEMBL15323685 | 0.86 | SLC7A5 (0.47) | METAP2METAP1RNPEPBHMTBHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111165710-A | Bifidobacterium bifidum probiotic solid beverage with cell aging resistance | 任彦芬 | 2020-05-19 | — | — | CN | claimed |
| CN-109090410-A | A kind of living body Chinese medicine compound probiotic drink and preparation method thereof | 杨声显 | 2018-12-28 | — | — | CN | claimed |
| CN-107821896-A | A kind of live body compound probiotic drink | 合肥海昭生物科技有限公司 | 2018-03-23 | — | — | CN | claimed |
| CN-104983746-A | Complex probiotics and preparation method | BIOSTIME GUANGZHOU HEALTH PRODUCTS LTD | 2015-10-21 | — | — | CN | claimed |
| US-20090070900-A1 | Novel cherkasky materials and novel use of biomolecules and biomasses | CHERKASKY ALEXANDER | 2009-03-12 | — | — | US | claimed |
| EP-4135722-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTIONS | Vector Vitale IP LLC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20220096525-A1 | NUCLEIC ACID THERAPEUTICS FOR GENETIC DISORDERS | GREENLIGHT BIOSCIENCES, INC. | 2022-03-31 | — | — | US | disclosed |
| WO-2021211660-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTIONS | VECTOR VITALE IP LLC (US) | 2021-10-21 | — | — | WO | disclosed |
| US-20210322467-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTIONS | VECTOR VITALE IP LLC (US) | 2021-10-21 | — | — | US | disclosed |
| CN-111165710-A | Bifidobacterium bifidum probiotic solid beverage with cell aging resistance | 任彦芬 | 2020-05-19 | — | — | CN | disclosed |
| CN-104940710-B | Healthy and free from worry Chinese medicine composition of tabasheer epilepsy and preparation method thereof | 彭雄彬 | 2019-03-05 | — | — | CN | disclosed |
| CN-109311808-A | Methionine production | 赢创德固赛有限公司 | 2019-02-05 | — | — | CN | disclosed |
| US-20060088900-A1 | Method for determining inhibition activity of a compound on one of the enzymes of the folate synthesis pathway | AVENTIS PHARMA S.A. (FR) | 2006-04-27 | — | — | US | disclosed |
| EP-1531716-A2 | METHODS FOR USING ADAMTS-12, AN INTEGRIN AND METALLOPROTEASE WITH THROMBOSPONDIN MOTIFS | Athersys, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1414993-A2 | SCREENING-METHOD FOR INHIBITORS OF FOLATE-SYNTHESIS-PATHWAY ENZYMES | Aventis Pharma S.A. (FR) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003103478-A2 | METHODS FOR USING ADAMTS-12, AN INTEGRIN AND METALLOPROTEASE WITH THROMBOSPONDIN MOTIFS | ATHERSYS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| CN-1433318-A | Vascular endothelial growth factor-2 | HUMAN GENOME SCIENCES INC (US) | 2003-07-30 | — | — | CN | disclosed |
| CN-1416354-A | Vascular endothelial growth factor 2 | HUMAN GENOME SCIENCES INC (US) | 2003-05-07 | — | — | CN | disclosed |
| WO-2003012132-A2 | SCREENING METHOD FOR INHIBITORS OF FOLATE SYNTHESIS PATHWAY ENZYMES | AVENTIS PHARMA S.A. (FR) | 2003-02-13 | — | — | WO | disclosed |
| EP-1281769-A1 | Screening-method for inhibitors of folate-synthesis-pathway enzymes | Aventis Pharma S.A. (FR) | 2003-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322467-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTIONS | ZC3HAV1, SLC30A6, SOD1 | METAP2 141/4885METAP1 68/4885RNPEP 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.